501948-05-6

501948-05-6 structure

Name: Rosabulin
Chemical Name: 2-[3-[(4-cyanophenyl)methyl]indolizin-1-yl]-N-(3-methyl-1,2-thiazol-5-yl)-2-oxoacetamide
CAS Number: 501948-05-6
Molecular Formula: C₂₂H₁₆N₄O₂S
Molecular Weight: 400.45300
Catalog: Signaling Pathways Cell Cycle/DNA Damage Microtubule/Tubulin
Create Date: 2018-03-15 08:00:00
Modify Date: 2024-01-10 10:59:22
Rosabulin is a potent microtubule inhibitor, with anti-cancer activities.

Name	2-[3-[(4-cyanophenyl)methyl]indolizin-1-yl]-N-(3-methyl-1,2-thiazol-5-yl)-2-oxoacetamide
Synonyms	UNII-6Z674O12T6 Rosabulin I01-9450 STA-5312

Description	Rosabulin is a potent microtubule inhibitor, with anti-cancer activities.
Related Catalog	Signaling Pathways >> Cell Cycle/DNA Damage >> Microtubule/Tubulin Signaling Pathways >> Cytoskeleton >> Microtubule/Tubulin Research Areas >> Cancer
In Vitro	Rosabulin demonstrates substantial anti-proliferative activity against a wide range of cancer cell linesin vitro, with IC50 values extending down into the nanomolar range. Rosabulin is inhibition of microtubule assembly and subsequent arrest of the cell cycle. Rosabulin is active against several tumor cell lines that express moderate to high levels of P-glycoprotein (Pgp), including lines insensitive to Taxol, Vincristine, and Adriamycin in which Pgp activity is a major contributor to the MDR phenotype[1].
In Vivo	Rosabulin has shown in vivo activity in several murine tumors as well as human tumor xenograft models, including drug resistant tumors[1].
References	[1]. Keizo Koya, et al. STA-5312, a novel tubulin inhibitor, demonstrates the anti-cancer activity against chemotherapy-resistant cancers. Proc Amer Assoc Cancer Res, Volume 45, 2004

HS Code	2934999090

24340-76-9

79-37-8

501948-43-2

~78%

501948-05-6

Literature: SBR Pharmaceuticals Corp. Patent: US2003/153759 A1, 2003 ;

104-85-8

501948-05-6

501948-45-4

501948-05-6

501948-43-2

501948-05-6

501948-42-1

501948-05-6

1443-80-7

501948-05-6

109-06-8

501948-05-6

HS Code	2934999090
Summary	2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%